<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1559">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140863</url>
  </required_header>
  <id_info>
    <org_study_id>HSK16149-302</org_study_id>
    <nct_id>NCT05140863</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week, Phase 3 Study to Evaluate the Efficacy and Safety of HSK16149 Capsules in Chinese Patients With Postherpetic Neuralgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the Efficacy and Safety of HSK16149 capsules in Chinese Postherpetic Neuralgia&#xD;
      Following 12 Weeks Treatment in Comparison to Placebo&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the change from baseline in ADPS between HSK16149 and placebo at week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>The mean change in average daily pain score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 [no pain] to 10 [worst possible pain]. The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the response rate between HSK16149 and placebo at week 12 (Proportion of subjects whose ADPS decreased by ≥30% and ≥50% from baseline )</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>Ratio of Participants Responding to Treatment, as Measured by Average Daily Pain Score (ADPS) Reduction from Baseline. The ADPS is used to determine categorical response rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change from baseline in ADPS between HSK16149 and placebo at week 1 to 12</measure>
    <time_frame>From week 1 to week 12</time_frame>
    <description>The mean change in average daily pain score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 [no pain] to 10 [worst possible pain]. The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change from baseline in Visual Analogue Scale（VAS） between HSK16149 and placebo at week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>VAS, in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change from baseline in Short Form McGill Pain Questionnaire (SF-MPQ) between HSK16149 and placebo at week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>Participants rate their pain in three parts of the questionnaire, which are combined into a single pain intensity score:&#xD;
Part 1 - fifteen descriptors of pain intensity, on a scale of 0 (none) to 3 (severe)&#xD;
Part 2 - a visual analog scale (VAS), in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain&#xD;
Part 3 - a Present Pain Intensity index in which the participant rates present pain intensity on a scale of 0 (no pain) to 5 (most intense pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change from baseline in Average Daily Sleep interference score（ADSIS） between HSK16149 and placebo at week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>he sleep interference scores on a scale of 0-10, where 0 = pain did not interfere with sleep to 10 = pain completely interfered with sleep. The weekly ADSIS is based on participants daily sleep interference scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the total consumption of Acetaminophen and Paracetamol and Dihydrocodeine Tartrate between HSK16149 and placebo during the trial</measure>
    <time_frame>From week 1 to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change from baseline in EQ-5D-5L between HSK16149 and placebo at week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>The change from baseline in total EuroQol-5-Domain-5-Level health questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE（adverse event） to evaluate the safety of HSK16149 during the trial</measure>
    <time_frame>From week 1 to week 12</time_frame>
    <description>Number and severity of AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of HSK16149 capsules in Chinese patients with Postherpetic Neuralgia</measure>
    <time_frame>Week 4,week 8,week 10,week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of HSK16149 capsules in Chinese patients with Postherpetic Neuralgia</measure>
    <time_frame>Week 4,week 8,week 10,week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">345</enrollment>
  <condition>Postherpetic Neuralgia</condition>
  <arm_group>
    <arm_group_label>HSK16149 20mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSK16149 20mg, orally twice a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HSK16149 40mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSK16149 40mg, orally twice a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, orally twice a day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK16149 20mg BID</intervention_name>
    <description>HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose</description>
    <arm_group_label>HSK16149 20mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK16149 40mg BID</intervention_name>
    <description>HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose</description>
    <arm_group_label>HSK16149 40mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo BID</intervention_name>
    <description>Placebo, orally twice a day, treatment period; 12-weeks fixed dose</description>
    <arm_group_label>Placebo BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent;&#xD;
&#xD;
          2. Males or females aged 18-75 years of age inclusive;&#xD;
&#xD;
          3. Outpatient, Patients can not stay in the hospital overnight;&#xD;
&#xD;
          4. Patients must have pain present for more than 1 months after the healing of the herpes&#xD;
             zoster skin rash;&#xD;
&#xD;
          5. At Screening, pain scale (VAS) of ≥40 mm;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Peripheral neuropathy or pain unrelated to PHN that may confuse the assessment of PHN;&#xD;
&#xD;
          2. Skin conditions in the area affected by neurupathy that could alter sensation;&#xD;
&#xD;
          3. Chronic systemic diseases that may affect subjects' participation in the study;&#xD;
&#xD;
          4. Severe hematologic, hepatic or renal dysfunction, the subject will be excluded&#xD;
             if:1)Neutrophils &lt; 1.5 × 109/L, or platelet &lt; 90 × 109/L, or hemoglobin &lt; 100 g/L, or&#xD;
             2)AST/ALT &gt; 2.5 × upper limit of normal (ULN), or TBIL &gt; 1.5 × ULN, or 3)Estimation of&#xD;
             glomerular filtration rate (eGFR) &lt; 60 mL/min / 1.73 m2, or 4)Creatine kinase &gt; 2.0 ×&#xD;
             ULN.&#xD;
&#xD;
          5. Uncontrolled diabetes(HbA1c≥11.0% at screening) ;&#xD;
&#xD;
          6. History of substance abuse or alcohol abuse;&#xD;
&#xD;
          7. Any active infections at screening;&#xD;
&#xD;
          8. HBsAg or HCV Ab positive, or HIV Ab positive, or serum TP Ab positive;&#xD;
&#xD;
          9. Inability or unwillingness to discontinue any other prohibited concomitant medications&#xD;
             (see Section 6.3);&#xD;
&#xD;
         10. Patients who have undergone neurolytic or neurosurgical therapy 1 week before&#xD;
             screening for postherpetic neuralgia;&#xD;
&#xD;
         11. Failure to response to previous treatment with pregabalin at doses ≥ 300 mg/d or&#xD;
             gabapentin at doses ≥ 1200 mg/d for treatment of PHN;&#xD;
&#xD;
         12. History of allergic or medically significant adverse reaction to investigational&#xD;
             products or their excipients, acetaminophen or related compounds;&#xD;
&#xD;
         13. History of suicidal behavior or attempted suicide;&#xD;
&#xD;
         14. Pregnant or preparing for pregnancy or breastfeeding during the study period, or&#xD;
             subjects were not willing to use reliable contraceptives methods from the date of ICF&#xD;
             signature until 28 days after the last trial drug administration, or planning to use&#xD;
             progesterone contraceptives during this period;&#xD;
&#xD;
         15. Mechanical operators who are engaged in high-altitude operations, motor vehicle&#xD;
             driving and other dangerous machinery operators;&#xD;
&#xD;
         16. Participated in another clinical study within 30 days prior to screening;&#xD;
&#xD;
         17. Other conditions unlikely to participate in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fangqiong Li</last_name>
    <phone>+8602867258840</phone>
    <email>lifangq@haisco.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dermatology Hospital of Chinese Academy of Medical Sciences</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qianjin Lu, M.D.</last_name>
      <phone>+8613787097676</phone>
      <email>qianlu5860@pumcderm.cams.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daying Zhang, B.A.</last_name>
      <phone>+8613507913595</phone>
      <email>zdysino@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>November 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 21, 2021</last_update_submitted>
  <last_update_submitted_qc>November 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

